Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells

Cancer Research

Volumn 65, Issue 24, 2005, Pages 11459-11468

  Riggi, Nicolò ^a   Cironi, Luisa ^a   Provero, Paolo ^b   Suvà, Mario Luca ^a   Kaloulis, Konstantinos ^c   Garcia Echeverria, Carlos ^d   Hoffmann, Francesco ^d   Trumpp, Andreas ^c   Stamenkovic, Ivan ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF TURIN   (Italy)

^c SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; HYBRID PROTEIN; RNA BINDING PROTEIN EWS; SOMATOMEDIN C; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CARCINOGENESIS; CHROMOSOME; CHROMOSOME 11; CHROMOSOME 24Q; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; EMBRYO; EWING SARCOMA; FIBROBLAST; GENE FLI 1; GENE TARGETING; HUMAN; HUMAN CELL; MESENCHYME CELL; MOLECULAR CLONING; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; TRANSCRIPTION INITIATION;

ANIMALS; BONE MARROW CELLS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P19; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PROTO-ONCOGENE PROTEIN C-FLI-1; SARCOMA, EWING'S; STEM CELLS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 29244447707     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1696     Document Type: Article

References (53)

1. Helman LJ, Meltzer P. Mechanisms of sarcoma development Nat Rev Cancer 2003;3:685-94.
2. Mackall CL, Meltzer PS, Helman LJ. Focus on sarcomas. Cancer Cell 2002;2:175-8.
3. Kovar H. Ewing's sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. Curr Opin Oncol 1998;10:334-42.
4. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001;20:5747-54.
5. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;35: 162-5.
6. May WA, Lessnick SL, Braun BS, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993;13:7393-8.
7. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligonucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997;99:239-47.
8. Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994;14: 3230-41.
9. Thompson AD, Braun BS, Arvand A, et al. EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma. EWS/FLI1 fusion gene. Oncogene 1996;13:2649-58.
10. Braun BS, Frieden R, Lessnick SL, May WA, Denny CT. Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis. Mol Cell Biol 1995;15:4623-30.
11. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet 1997;17: 495-7.
12. Fukuma M, Okita H, Hata J-I, Umezawa A. Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene 2003;22:1-9.
13. Wai DH, Schaefer K-L, Schramm A, et al. Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. Int J Oncol 2002;20:441-51.
14. Hahm K-B, Cho K, Lee C, Im Y-H, et al. Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999;23:222-7.
15. WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 2003;278:15105-15.
16. Dauphinot L, De Oliveira C, Melot T, et al. Analysis of the expression of cell cycle regulators in Ewing cell lines:EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 2001;20:3258-65.
17. Zwerner JP, Guimbellot J, May WA. EWS/FLI function varies in different cellular backgrounds. Exp Cell Res 2003;290:414-9.
18. Thompson AD, Teitell MA, Arvand A, Denny CT. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. Oncogene 1999;18:5506-13.
19. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002;1:393-401.
20. Deneen B, Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/DLI1 mediated transformation. Oncogene 2001;20:6731-41.
21. Wei G, Antonescu CR, de Alava E, et al. Prognostic impact of INK4A deletion in Ewing's sarcoma. Cancer 2000;89:793-9.
22. Kovar H. Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 2005;15:189-96.
23. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-9.
24. Tanaka TS, Jaradat SA, Lim MK, et al. Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray. Proc Natl Acad Sci U S A 2000;97:9127-32.
25. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
26. Tsai CA, Chen YJ, Chen JJ. Testing for differentially expressed genes with microarray data. Nucleic Acids Res 2003;31:e52.
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 1995;57:289-300.
28. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-9.
29. Lin PP, Brody RI, Hamelin AC, Bradner JE, Healey JH, Ladanyi M. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res 1999;59:1428-32.
30. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95:9-20.
31. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004;103:1662-8.
32. Sun S, Guo Z, Xiao X et al. Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells 2003;21:527-35.
33. Ammann G, Zoubek A, Salzer-Kuntschnik M, Windhager R, Kovar H. Relation of neuroglial marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family. Hum Pathol 1999;30:1058-64.
34. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
35. Nagai M, Tanaka S, Tsuda M, et al. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 α. Proc Natl Acad Sci U S A 2001;98:3843-8.
36. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88:386-401.
37. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B. Identification and classification of p-53-regulated genes. Proc Natl Acad Sci U S A 1999;96:14517-22.
38. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998;12:2424-33.
39. Pollack MN, Schernhamer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
40. Scotlandi K, Benini S, Nanni P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 1998;58:4127-31.
41. Scotlandi K, Avnet S, Benini S, et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 2002;101:11-6.
42. Benini S, Manara MC, Cerisano V, et al. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer 2004;108:358-66.
43. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541: a novel, potent and selective inhibitor of the IGF-1R kinase. Cancer Cell 2004;5:231-9.
44. Torchia EC, Jaishankar S, Baker SJ. Ewing's tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res 2003;63:3464-8.
45. Nowell PC. Tumor progression: a brief historical perspective. Semin Cancer Biol 2002;12:261-6.
46. Li Z-Y, Liu D-P, Liang C-C. New insight into the molecular mechanisms of MLL-associated leukemia. Leukemia 2005;19:183-90.
47. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology (Am Soc Hematol Educ Program) 2004;80-97.
48. Perez-Losada J, Pintado B, Gutierrez-Adan A, et al. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene 2000;19:2413-22.
49. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-83.
50. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. Id2 is a retinoblastoma protein target and mediates signaling by Myc oncoproteins. Nature 2000;407:592-8.
51. Lasorella A, Uo T, Iavarone A. Id proteins at the crossroad of development and cancer. Oncogene 2004;20:8326-33.
52. Lasorella A, Boldrini R, Dominici C, et al. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 2002;62:301-6.
53. Adhikary S, Eilers M. transcriptional regulation and transformation by myc proteins. Nat Rev Mol Cell Biol 2005;6:635-45.